Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor
Cet article passe en revue les travaux récents sur l'efficacité de l'enzalutamide, un inhibiteur de la signalisation du récepteur des androgènes, pour le traitement des patients atteints d'un cancer de la prostate résistant à la castration de stade métastatique
Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer (mCRPC) who progressed to docetaxel. The anti-tumour activity and safety of enzalutamide has been demonstrated in a phase III clinical trial, showing a benefit in overall survival, which was the primary endpoint. There are no head-to-head studies comparing the different treatment options in this subset of patients. In this article, most relevant data published in the literature have been reviewed, with special attention to the therapeutic alternatives currently available for postdocexatel mCRPC patients, emphasizing the mechanisms of action of the different drugs, efficacy and quality of life-related aspects.